Mesothelioma Clinical Trials (2026): 70 Recruiting Interventional Studies

Last updated: March 9, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Unresectable / Advanced Mesothelioma

First-line and beyond for patients not eligible for surgery:

• Checkpoint + TKI combinations:
  • NCT06318286 - Pembrolizumab + chemotherapy + Lenvatinib
  • NCT05188859 - Sintilimab + Anlotinib + platinum doublet
  • NCT06543069 - Sintilimab + Bevacizumab + Pemetrexed/Cisplatin
• Novel immunotherapy:
  • NCT04400539 - 5-ALA photodynamic therapy + immunotherapy

Resectable / Surgery Combinations

Neoadjuvant and adjuvant immunotherapy with surgery:

• NCT05932199 - Neoadjuvant Durvalumab + Tremelimumab ± chemotherapy
• NCT03760575 - Pembrolizumab + chemotherapy + image-guided surgery
• NCT05647265 - Immunotherapy before surgery (sarcomatoid subtype)
• NCT07121374 - Neoadjuvant chemo-immunotherapy for selected inoperable cases

Peritoneal Mesothelioma

Trials specifically for peritoneal disease:

• NCT06057935 - Additional chemotherapy after surgery

Trials by Treatment Approach

Checkpoint Inhibitors (19 trials)

PD-1/PD-L1 and CTLA-4 inhibitors, often combined with chemotherapy or targeted agents. View all →

Mesothelin-Targeted Therapies (6 trials)

CAR-T cells, antibody-drug conjugates, and other therapies targeting mesothelin, highly expressed in mesothelioma. View all →

• NCT06885697 - Anti-Mesothelin CAR T cells
• NCT06051695 - Logic-gated mesothelin CAR-T
• NCT05568680 - SynKIR-110 for mesothelin-expressing tumors

Surgery Combinations (13 trials)

Pleurectomy/decortication or extrapleural pneumonectomy combined with systemic therapy. View all →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.